



**5<sup>th</sup> July 2023** (9.00am- 9.30am – Registration & Seating) @ Hitex Exhibition Center, Hyderabad

9.30am- 11.30am: Inaugural Program

11.30am-1.00pm : Visit to Exhibition

1.00pm- 2.00pm : Luncheon

Panel Sessions

**Day-1 : 5<sup>th</sup> July 2023**

**Session- 1** : 5<sup>th</sup> July 2023 @ 2.30 – 3.30 pm

Panel Session <b>Quality Compliance &amp; Patient Safety</b> 5 <sup>th</sup> July 2023 @ 2.30 – 3.30 pm	
Context	<p>Maintaining the Quality of pharmaceutical products is crucial to guaranteeing the patient's safety, failing which could have long-term ramifications for the global public's confidence on Indian medicines.</p> <p>With the recent WHO Medical alerts on supply of contaminated medications have surfaced the non-compliance by units to the GMP and the product Quality norms, the global regulatory agencies are making efforts to create awareness among pharmaceutical manufacturers, contract manufacturers regarding the potential public health burden posed by contaminated drug products.</p> <p>The Indian pharma units especially the MSME sector are facing new challenges under resource poor settings to meet global as well as domestic health care expectations.</p>
Discussion Areas	<ul style="list-style-type: none"> <li>● Significance of Quality by Design Concept</li> <li>● Manufacturing challenges that lead to DEG contamination in pharmaceutical products and their excipients.</li> <li>● Importance of Excipient testing in Pharma manufacturing.</li> <li>● Key global excipient regulations for generic drug development</li> <li>● Market Control &amp; Surveillance of Excipients</li> <li>● Regulatory challenges and expectations: Risk assessment, confirmatory testing, and control strategy for all products.</li> </ul>
Moderator	<b>Dr.Viranchi Shah</b> , <i>President, IDMA</i>
Speakers	<ol style="list-style-type: none"> <li>1. <b>Dr.Rajeev Singh Raghuvanshi</b>, DCG(I)</li> <li>2. <b>Dr.Chava Satyanarayana</b>, <i>Chief Executive Officer, Laurus Labs Ltd</i></li> <li>3. <b>Mr Girish Kapur</b>, VP &amp; India Site head, USP</li> <li>4. <b>Dr.P.Veer Raju</b>, <i>Vice President, Regulatory Affairs- QuagenPharma LLC, USA</i></li> <li>5. <b>Dr. Ranga Reddy Burri</b>, <i>President Infection Control Academy and Honorary Professor University of Hyderabad</i></li> </ol>

**Session- 2 : ON INVITATION ONLY**

**5<sup>th</sup> July 2023 @ 4.00 – 5.30 pm**

<b>CEO Roundtable on Potential Collaborations among G20 Countries: Business Prospects for India</b>	
<b>Context</b>	<p>The Indian pharmaceutical industry has emerged as a global leader in the production and export of generic drugs &amp; has gained significant recognition for its ability to manufacture high-quality medications at affordable prices.</p> <p>While India’s G20 Presidency focuses on strengthening cooperation in the pharmaceutical sector with a focus on access and availability to safe, effective, quality and affordable medical countermeasures (Vaccines, Therapeutics and Diagnostics) along with health emergencies prevention, preparedness and response under Health working group, exploring export opportunities in G20 countries by Indian pharma becomes crucial for its sustained expansion and global presence.</p> <p>The challenge of meeting the healthcare needs of G20 nations requires careful consideration. With the diverse healthcare requirements of these countries, the industry must address issues such as regulatory compliance, intellectual property rights, and market competition. It needs to focus on research and development, innovation, and strategic collaborations to develop tailored solutions for the healthcare challenges faced by G20 nations. By leveraging its strengths in cost-effective manufacturing, expertise in generic drugs, and a skilled workforce, the Indian pharmaceutical industry can rise to the challenge and make a significant contribution to meeting the healthcare needs of G20 nations.</p>
<b>Discussion Areas</b>	<ul style="list-style-type: none"> <li>● Global Economic conditions &amp; Policy measures for combating healthcare expenditures leading to enhanced Generic Uptake</li> <li>● Impact of price control measures in some G20 countries on the pricing and profitability of pharma producers</li> <li>● Off Patented blockbuster drugs among G20 countries, benefiting Indian Pharma</li> <li>● Challenges in complying with diverse regulatory frameworks among G20 countries.</li> <li>● Potential areas of collaboration in Research and Development (R&amp;D), JV &amp; Contract Manufacturing etc</li> <li>● Key strategies Indian pharmaceutical companies can adopt to enhance their market penetration in G20 countries</li> </ul>



Moderator	<b>Dr. Dinesh Dua</b> , Former Chairman of Pharmexcil
	<ol style="list-style-type: none"> <li>1. <b>Mr.Emanuel</b>, CEO, Belcher Farmaceutica, Brazil</li> <li>2. <b>Mr.Aman Madan</b>, MD, Neo health Group, Australia</li> <li>3. <b>Mr.Umesh Kumar</b>, Director, Cellchem pharmaceuticals Inc, Canada</li> <li>4. <b>Mr.Tomas Echenique</b>, President, Dimafo S.A, Argentina</li> <li>5. <b>Dr.Denys Richsko</b>, CEO-Allgoal Medical, Turkey</li> <li>6. <b>Mr.Moosa Areef</b>, COO, Kiara Health (PTY) Ltd, South Africa</li> <li>7. <b>Mr.Sudarshan Jain</b>, Secretary General, Indian Pharmaceutical Alliance IPA</li> <li>8. <b>Mr.Madan Mohan Reddy</b>, Wholetime Director, Aurobindo Pharma</li> <li>9. <b>Dr. B. Parthasaradhi Reddy</b>, Chairman, Hetero Group of Companies*</li> <li>10. <b>Mr. Venkat Jasti</b>, Chairman &amp; CEO, Suven Life Sciences Limited*</li> <li>11. <b>Mr.S.V.Veeramani</b> Chairman of Pharmexcil &amp; CMD, Fourrts</li> <li>12. <b>Mr.Namit Joshi</b>, Vice Chairman of Pharmexcil &amp; Commercial Director, Centrient Pharmaceuticals</li> <li>13. <b>Mr.S.M.Mudda</b>, Managing Director, Misom Labs</li> <li>14. <b>Dr. Mahesh Bhalgat</b>, COO, Syngene International Ltd</li> </ol>

7.00 pm- 8.30pm – Cultural Program

8.30pm- 10.00pm - Networking Dinner

**Day-2 : 6<sup>th</sup> July 2023**

**Session- 3 :**

**6<sup>th</sup> July 2023 @ 10.00 – 11.00 am**

Panel Session <b>BIOPHARMACEUTICLAS</b>	
Moderator	<b>Dr. Murali</b> , President, Council of Presidents, ABLE
Discussion Areas	To discuss the urgency for capacity building and expanding the scope of the National Biopharma Mission to make Bio manufacturing a \$100 B in India by 2025 and double it by 2030.
Panelists	<ol style="list-style-type: none"> <li>1. <b>Dr. Subhra Ranjan Chakarabarti</b>, Director - Operations, BIRAC</li> <li>2. <b>Mr. Nitish Kumar</b>, Head of Customer Applications, Downstream, India, Merck Life Sciences</li> <li>3. <b>Mr. Ganesh Reddy</b>, Global Head - Biologics Manufacturing, Biocon Biologics Limited*</li> <li>4. <b>Ms. Jugnu Jain</b>, CEO, Sapien Biosciences</li> <li>5. <b>Dr. Devesh Bhardwaj</b>, Head Biotechnology, Mankind Pharma</li> </ol>

**Session- 4 :**

**6<sup>th</sup> July 2023 @ 12.00 – 1.00 pm**

Panel Session <b>VACCINES</b>	
Moderator	<b>Dr. Murali</b> , President, Council of Presidents, ABLE
Discussion Areas	India as a vaccine manufacturing hub is well accepted globally. The emergence of technologies like mRNA and the urgent need to invest more in vaccine R&D and the role stakeholders like Union State, industries and others will be discussed.
Panelists	<ol style="list-style-type: none"> <li>1. <b>Dr. Vinod Pantula</b>, Head - Vaccine Development, Dr. Reddys Laboratories</li> <li>2. <b>Dr. Swarnendu Kaviraj</b>, Executive Director R&amp;D, Genova Biosciences</li> <li>3. <b>Ms. Mourya Boda</b>, Chairperson &amp; Managing Director, Brilliant Biopharma</li> <li>4. <b>Mr. Brij B Baluni</b>, Sr. GM– Manufacturing- Zydus Group</li> <li>5. <b>Mr. Atin Tomar</b>, Co-Founder &amp; CEO, Yapan Bio</li> </ol>